GLP-1 Medications and Testosterone: What the Clinical Evidence Shows

Multiple systematic reviews confirm that GLP-1 drugs increase testosterone in men with obesity. Here's the data on how much, why it happens, and what it means for male reproductive health.

One of the most consistent findings in recent GLP-1 research has nothing to do with weight loss per se — it's the effect on testosterone. Multiple systematic reviews published between 2025 and 2026 have now established that GLP-1 receptor agonists significantly increase total testosterone levels in men with obesity and metabolic dysfunction. This has major implications for the millions of men dealing with obesity-related low testosterone.

The Numbers: How Much Does Testosterone Increase?

A meta-analysis published in BMC Urology (November 2025) pooled data from studies including 680 male patients and found a standardized mean difference of 1.39 ng/mL in total testosterone after GLP-1 treatment. BMC Urol 2025

To put this in clinical context: the American Urological Association defines low testosterone as any value below 300 ng/dL. A study presented at ENDO 2025 (the Endocrine Society's annual meeting) tracked 110 men with obesity on GLP-1 drugs for 18 months. At baseline, only about half had total testosterone above 300 ng/dL. After 18 months, that proportion rose to 77%. The average participant lost about 26 pounds. Pharmacy Times 2026

Why GLP-1s Boost Testosterone: The Mechanisms

The testosterone increase appears to be driven by two pathways, both supported by evidence:

1. Weight Loss Restores the HPG Axis

Obesity causes what endocrinologists call functional hypogonadism — excess adipose tissue converts testosterone to estradiol via aromatase, while inflammatory cytokines from fat cells suppress the hypothalamic-pituitary-gonadal (HPG) axis. Losing weight reverses both of these mechanisms. The meta-analysis found a significant negative correlation between testosterone improvement and percentage change in weight and BMI, confirming that more weight lost equals more testosterone recovered.

2. Direct GLP-1 Receptor Effects on Reproductive Tissue

GLP-1 receptors are expressed in testicular tissue, including Leydig cells (which produce testosterone) and Sertoli cells (which support spermatogenesis). Preclinical studies show that GLP-1 receptor activation stimulates testosterone production through cAMP/PKA and PI3K/Akt signaling pathways — independent of weight loss. Urology 2026

This dual mechanism is why GLP-1 drugs may be more effective at restoring testosterone than diet-only weight loss of the same magnitude.

Semen Quality and Fertility: A Surprising Advantage

Unlike testosterone replacement therapy (TRT), which suppresses the body's natural sperm production and can cause infertility, GLP-1 medications preserve or improve gonadotropin function. A 2025 systematic review of 371 men found that GLP-1 treatment improved sperm concentration, total sperm count, motility, and morphology — particularly in obese men. ICS 2025

This makes GLP-1 medications a potential alternative to TRT for men with obesity-related hypogonadism who want to preserve fertility — a scenario that is common in men in their 30s and 40s.

Important Caveats

The testosterone-boosting effect is primarily observed in men who are obese or have metabolic dysfunction at baseline. Studies of metabolically healthy, normal-weight men show no significant change in androgen levels on GLP-1 therapy. In other words, these drugs restore suppressed testosterone rather than boosting it beyond normal levels. J Sex Med 2025

Most studies to date are relatively small (under 200 participants), and the longest follow-up is 18 months. Larger randomized controlled trials with longer duration are needed to confirm these findings and establish GLP-1 medications as a formal treatment option for obesity-related hypogonadism.